Drug · CHEMBL975
MESNA
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MESNA. Drugs and targets, record CHEMBL975. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL975
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases44
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| acute myeloid leukemia | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| lymphoma | Phase 2 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005062 |
| neuroblastoma | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005072 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| hematopoietic and lymphoid cell neoplasm | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0044881 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| B-cell chronic lymphocytic leukemia | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
| aplastic anemia | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0015909 |
| myelodysplastic syndrome | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
1 to 10 of 44Source Open Targets
See all 44 diseasesTrials85
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00177047 | Autologous Transplant for Multiple Myeloma | Phase 2/3 | 363 | 2021-11-09 | mesna | Its name | ClinicalTrials.gov |
| NCT00703820 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | Phase 3 | 324 | 2018-04-02 | mesna | Its name | ClinicalTrials.gov |
| NCT00671658 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | Phase 2 | 220 | 2020-12-03 | mesna | Its name | ClinicalTrials.gov |
| NCT01010217 | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | Phase 2 | 176 | 2020-01-07 | mesna | Its name | ClinicalTrials.gov |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | Phase 1 | 150 | 2017-02-09 | mesna | Its name | ClinicalTrials.gov |
| NCT00067002 | Randomized Double Cord Blood Transplant Study | Phase 2 | 110 | 2019-05-01 | mesna | Its name | ClinicalTrials.gov |
| NCT00274924 | Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma | Phase 2 | 100 | 2014-02-24 | mesna | Its name | ClinicalTrials.gov |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | Phase 2 | 69 | 2026-03-04 | mesna | Its name | ClinicalTrials.gov |
| NCT00290433 | Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma | Phase 2 | 55 | 2020-09-23 | mesna | Its name | ClinicalTrials.gov |
| NCT00038610 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | Phase 2 | 54 | 2015-09-18 | mesna | Its name | ClinicalTrials.gov |
1 to 10 of 85
See all 85 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Un-Manipulated CB Arm vs Expanded CB Arm: Number of Participants With Engraftment | 45 of 52 | 44 of 53 | 105 | NCT00067002 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: serious adverse events | 9 of 52 | 4 of 53 | 105 | NCT00067002 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: Rate of Acute Graft Versus Host Disease (GVHD) | 29 of 45 | 24 of 44 | 89 | NCT00067002 | Trial comparisons |
| Mesna vs Saline: serious adverse events | 1 of 32 | 1 of 32 | 64 | NCT01205503 | Trial comparisons |
| Standard vs Mesna: Compare Number of Patients With Capsular Contracture in Mesna Group vs Standard of Care | 2 of 9 | 4 of 11 | 20 | NCT00758667 | Trial comparisons |
| Standard vs Mesna: Compare Number of Patients With Adverse Events in the Mesna Group vs the Standard of Care | 0 of 9 | 0 of 11 | 20 | NCT00758667 | Trial comparisons |
| Standard vs Mesna: serious adverse events | 0 of 9 | 0 of 11 | 20 | NCT00758667 | Trial comparisons |
| Phase II Window With Protracted Etoposide vs Phase II Window With Bolus Etoposide: Event Free Survival in Children With High Risk Neuroblastoma Treated on This Regimen. | 2 of 7 | 1 of 6 | 13 | NCT00578864 | Trial comparisons |
Phase II Window With Protracted Etoposide vs Phase II Window With Bolus Etoposide: Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With High Risk Neuroblastoma Tumors. | 1 of 7 | 2 of 6 | 13 | NCT00578864 | Trial comparisons |
| Phase II Window With Protracted Etoposide vs Phase II Window With Bolus Etoposide: Overall Survival in Children With High Risk Neuroblastoma Treated on This Regimen. | 3 of 7 | 2 of 6 | 13 | NCT00578864 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials43
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Paced Visual Serial Addition Test | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL975
GET https://conductscience.org/api/drugs/v1/CHEMBL975/diseases?page=2